There are currently 1094 clinical trials in Rochester, Minnesota looking for participants to engage in research studies. Trials are conducted at various facilities, including Mayo Clinic, Mayo Clinic in Rochester, Mayo Clinic - Rochester and Mayo Clinic Cancer Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
NCT03678025
Recruiting
This phase III trial studies how well standard systemic therapy with or without definitive treatment (prostate removal surgery or radiation therapy) works in treating participants with prostate cancer that has spread to other places in the body. Addition of prostate removal surgery or radiation therapy to standard systemic therapy for prostate cancer may lower the chance of the cancer growing or spreading.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
08/14/2024
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Castration Levels of Testosterone, Metastatic Prostatic Adenocarcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
Register for Updates
Prospective Sinonasal Cancer Multi-institution Study
NCT04755855
Recruiting
This is a multi-institution prospective study of patients with sinonasal malignancies. The goal of this study is to learn more about the course of sinonasal cancer, treatment outcomes, and patient quality of life. In addition, central mutational and genomic analysis of tumor tissue will be evaluated.
Gender:
ALL
Ages:
Between 30 days and 99 years
Trial Updated:
08/14/2024
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Sinonasal Carcinoma
Register for Updates
Genetic Markers of Cardiovascular Disease in Epilepsy
NCT02824822
Recruiting
Epilepsy is a common condition which affects over 3 million people in the US. Patients with uncontrolled epilepsy have a lifetime risk of sudden unexpected death (SUDEP) of 35%, which is greatest in those under 40 years of age. The exact mechanisms and causes are not understood but can be due to underlying conditions which affect the heart and brain, which may lead to dangerous heart rhythms and death. Some of these conditions which affect heart and brain have an identifiable genetic cause. This... Read More
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
08/13/2024
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Epilepsy, Seizures, Syncope, Channelopathy, Cardiomyopathies
Register for Updates
US National OCS Liver Perfusion (OLP) Registry
NCT05940857
Recruiting
This Registry is a sponsor-initiated, multi-center, observational, post-approval registry with an independent academic oversight. TransMedics has contracted with United Network for Organ Sharing (UNOS) the Federal manager of the U.S. national transplant outcomes registry to obtain data that is routinely collected by the Organ Procurement and Transplantation Network (OPTN) on all transplanted organs in the U.S. for both the OCS liver transplanted patients as well as patients transplanted using o... Read More
Gender:
ALL
Ages:
All
Trial Updated:
08/13/2024
Locations: Mayo Clinic Hospital Minnesota, Rochester, Minnesota
Conditions: Liver Transplant
Register for Updates
Treatment of Patients With Recurrent High-Grade Glioma With APG-157 and Bevacizumab
NCT06011109
Recruiting
The goal of this interventional study is to evaluate the efficacy of APG-157 in combination with Bevacizumab in subjects with recurrent high-grade glioma. The main questions the study aims to answer are: * Progression-free and overall survival of patients receiving this combination; * Quality of Life (QOL); and * Tumor response on imaging The participants will take APG-157 daily by dissolving two pastilles in their mouth at around breakfast, lunch and dinner time (total of six pastilles per da... Read More
Gender:
ALL
Ages:
19 years and above
Trial Updated:
08/13/2024
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Glioma, Glioblastoma Multiforme
Register for Updates
An Open-Label, Multiple-Center, Phase IIa/IIb Clinical Trial to Evaluate the Efficacy, Safety and Tolerability of VG161 as Monotherapy and in Combination With Nivolumab for Treatment of Patients With Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma
NCT05223816
Recruiting
Safety Run-in Cohort (cohort 1): 10 patients will be treated with IT injection of VG161 in the cohort 1 at dose level of 1.0x10E8 PFU x 3 days. Monotherapy Cohorts (Cohort 2 and 3) Cohort 2 (HCC) This part is a single-agent, single one-dose level and single-arm design. Approximately 39 subjects will be enrolled in the study to receive VG161. In the first stage, 21 subjects will be enrolled. If there is only 1 or fewer subjects has been observed with objective response and no more than 12 (\<13... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/07/2024
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma
Register for Updates
Exercise Response in Humans With Obesity
NCT05857150
Recruiting
This study is being done to understand how chronic inflammation affects muscle function and responses to exercise.
Gender:
ALL
Ages:
Between 20 years and 45 years
Trial Updated:
08/05/2024
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Obese
Register for Updates
OMEGA: Outcome Measures in Eosinophilic Gastrointestinal Disorders Across the Ages
NCT02523118
Recruiting
The purpose of this observational study is to find the best measures to define how well a person with eosinophilic disorder is doing. People with EoE, EoG, EoN and EoC normally undergo endoscopy and/or colonoscopy where cells are collected for microscopic analysis. Treatments are then decided based on how the cells look. We are aiming to compare different tissue components such as inflammatory cell types with clinical symptoms. We want to see if scores on standard questionnaires can give us an i... Read More
Gender:
ALL
Ages:
3 years and above
Trial Updated:
08/02/2024
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Eosinophilic Gastrointestinal Disorders (EGIDs), Eosinophilic Esophagitis, Eosinophilic Colitis, Eosinophilic Gastritis, Eosinophilic Gastroenteritis
Register for Updates
Accuracy of Cardiac Acoustic Biomarkers Recorded by the Wearable Cardioverter Defibrillator
NCT04292405
Recruiting
Evaluate data accuracy of cardiac acoustic biomarkers (CABs) recorded by the Wearable Cardioverter Defibrillator (WCD) as compared to the AUDICOR AM acoustic cardiography recorder.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/02/2024
Locations: MAYO Clinic, Rochester, Minnesota
Conditions: Heart Failure
Register for Updates
Improving the Quality of Dementia Care Through Innovative Redesign of the Memory Care Environment
NCT04350060
Recruiting
Research study is being done to demonstrate novel opportunities to transform the way the dementia community is cared for.
Gender:
ALL
Ages:
Between 65 years and 100 years
Trial Updated:
07/29/2024
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Dementia
Register for Updates
Cardiotoxic Effects of Chemotherapy in Patients With Sarcomas: A Two and Three-dimensional Echocardiographic Speckle Tracking Imaging Study
NCT06511388
Recruiting
This study is being done to identify markers that will allow researchers to identify in advance patients with sarcomas who are at highest risk for developing heart failure related to chemotherapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/19/2024
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Sarcoma
Register for Updates
A Phase 2 Study of VLX-1005 Versus Placebo in Suspected Heparin Induced Thrombocytopenia
NCT05785819
Recruiting
The purpose of this study is to evaluate the efficacy and safety of VLX-1005, a 12-lipoxygenase (12-LOX) enzyme inhibitor in treating heparin induced thrombocytopenia (HIT). Participants with suspected HIT will receive the usual standard of care, and will be assigned randomly to either VLX-1005 or placebo treatment. The study will measure important outcomes including platelet count, stroke, pulmonary embolus (clot to the lungs) and bleeding.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/12/2024
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Thrombocytopenia, Immune, Heparin Induced Thrombocytopenia
Register for Updates